Immunology and inflammation market: A wave of investment

Investment in the field of inflammatory diseases has recently attracted significant interest within the biopharma industry. The market is expected to grow substantially in the coming years, driven by scientific advancements and unmet medical needs. Several large acquisitions and fundraisings have occurred in 2024, including Roche’s acquisition of Telavant, Merck & Co.’s buyout of Prometheus Biosciences, and Johnson & Johnson’s acquisitions of two immune-focused companies.